Insights from 2023 ASH Annual Meeting
I

ASH 2023 Insights: "The Impact of Inotuzumab Ozogamicin Treatment on Brexu-Cel Outcomes in Adults With R/R B-ALL"

By Insights from 2023 ASH Annual Meeting FEATURING Ibrahim Aldoss
By Insights from 2023 ASH Annual Meeting FEATURING Ibrahim Aldoss
140 views
December 29, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Related Content

AUTOPLAY
50:34
Scripps MD Anderson Cancer Center

The Cure of Leukemias in the Next Decade: An Optimist’s View

Feat. H. Kantarjian
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
14:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Immunotherapies in Acute Leukemias: 2024 Update

Feat. C. Lai
04:02
Michael Burke

Updated Results from the BLAST and TOWER Studies: Safety and Efficac…

07:06
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Putting the CAR-T Before the Horse - Impr…

Feat. L. Shune
40:21
Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

Overview of Hematopoietic Cell Transplantation

Feat. R. Salit
28:07
Indy Hematology Review

Controversies and Recommendations for the Treatment of ALL and Lymph…

Feat. W. Stock
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
04:11
Total Health

ASCO 2022 Updates in Leukemia and MDS

Feat. D. Sallman
11:02
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Asciminib Combined With Dasatinib and Predn…

Feat. M. Luskin
17:51
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

Chronic GVHD: A Case-Based Discussion

Feat. L. Perry
42:06
UNC Lineberger Comprehensive Cancer Center

Let’s Take a BiTE Out of CRS and Neurotoxicity

Feat. B. Kikani
37:03
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: ALL

Feat. E. Jabbour
27:47
City of Hope

Chronic GVHD: Review Advances in Prevention, Novel Endpoints, and Ta…

Feat. I. Amanam
28:57
Total Health

Highlights From Key Hematology Trials at ASCO® 2023

Feat. J. Strauss
48:05
Yale Cancer Center

ALL - Progress in Research and Therapy in 2022

Feat. H. Kantarjian
17:38
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

Curative Potential of CAR T-Cell Therapy for ALL

Feat. S. Grupp
11:18
Talha Badar

Targeting CD38 in Acute Leukemias: Current Data and Ongoing Clinical…

03:03
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Olverembatinib (HQP1351) Overcoming Ponatin…

Feat. E. Jabbour
05:38
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Revumenib Monotherapy in Pts With R/R KMT2A…

Feat. I. Aldoss